Company patents
City of Hope
City of Hope's patent strategy is heavily concentrated in pharma_biotech, with Pharmaceutical Preparations (72.4% of portfolio) and Peptides & Proteins (51.4% of portfolio) being dominant areas, both showing a rebound in 2025 with +9.4% and +20.5% YoY growth respectively, after declines in 2024. Despite this focus, it's surprising to see a significant shift away from Medical Diagnostics & Surgery, which saw a -100.0% decline in 2025, indicating a deprioritization in this area.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
319 US filings (since 2023) · 10 categories · 23 themes
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Therapeutic approaches involving the use of living cells, often genetically modified or ex vivo activated, to treat diseases, particularly cancer, by modulating immune responses or replacing damaged cells.
Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.
Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.
Methods and compositions for identifying, quantifying, or characterizing specific biological molecules (e.g., nucleic acids, proteins, metabolites, antibodies) or microbial species, often for diagnostic, prognostic, or quality control applications.
Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.
Development of small molecules, often bifunctional (e.g., PROTACs) or molecular glues, that induce the ubiquitin-proteasome system or autophagy to selectively degrade specific disease-causing proteins.
Identification and measurement of specific nucleic acid sequences (DNA, RNA), their expression levels, or epigenetic modifications (e.g., methylation) as indicators for disease presence, progression, risk, or treatment response.
Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.
Assays leveraging CRISPR-Cas systems (e.g., Cas12, Cas13) for highly specific and sensitive detection of target nucleic acids, often involving collateral cleavage activity or reporter molecules.
Development and application of therapeutic proteins or peptides produced through recombinant DNA technology, including fusion proteins and modified growth factors.
Development and use of engineered biological systems, such as organ-on-a-chip devices, dynamic hydrogels, or genetically modified cells, to mimic physiological conditions, study disease mechanisms, screen compounds, or develop cell-based therapies.
Modification of protein or peptide sequences, structures, or post-translational modifications (e.g., glycosylation, lipidation) to enhance their stability, solubility, delivery, or therapeutic efficacy.
Methods and reagents designed to improve the specificity, efficiency, or yield of nucleic acid capture, ligation, amplification, or library preparation steps, particularly for sequencing applications or quantitative analysis.
Design and application of devices that are inserted into the body or implanted to treat diseases, modulate physiological functions, or repair anatomical structures.
Systems and methods for non-invasive or minimally invasive collection and analysis of physiological data (e.g., blood pressure, electrolytes, genetic markers, B cell repertoire) to assess patient health status, screen for conditions, or aid in diagnosis.
Methods and kits for amplifying nucleic acids at a constant temperature, enabling faster results and point-of-care applications, often used for pathogen or contamination detection.
Focuses on the mechanical design, articulation, and actuation of hand-held or robotic surgical instruments, including improvements in stapling, cutting, grasping, and tissue manipulation.
Self-contained or modular devices designed to automate and integrate multiple steps of molecular diagnostic assays, from sample preparation to result interpretation, often for point-of-care or high-throughput applications.
Systems and methods that use imaging technologies, computer vision, and augmented reality to provide real-time guidance, localization, and visualization during surgical procedures or for detailed anatomical assessment.
Utilizing machine learning, particularly deep learning, to analyze medical data such as images, sensor readings, or physiological signals for disease prediction, diagnosis, or treatment assessment.
Patents
Showing 1-10 of 542